vidarabine has been researched along with Neoplasms, Pleural in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbarino, M; Bottaro, M; Cipollini, M; Corrado, A; Dell'Anno, I; Gemignani, F; Giordano, A; Landi, S; Luzzi, L; Martin, SA; Melaiu, O; Melani, A; Paolicchi, E; Silvestri, R | 1 |
| Ijichi, O; Ikarimoto, N; Ishikawa, S; Kawano, Y; Kodama, Y; Manago, K; Nishikawa, T; Okamoto, Y; Shinkoda, Y; Tanabe, T | 1 |
2 other study(ies) available for vidarabine and Neoplasms, Pleural
| Article | Year |
|---|---|
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Survival; Drug Repositioning; Gene Expression Regulation, Neoplastic; Humans; Mesothelioma; Pleural Neoplasms; Risedronic Acid; STAT1 Transcription Factor; Vidarabine | 2021 |
Rapid progression of metastatic osteosarcoma after initiation of a reduced-intensity conditioning regimen with immunosuppressive fludarabine.
Topics: Antineoplastic Agents; Bone Neoplasms; Child; Disease Progression; Fatal Outcome; Female; Humans; Immunosuppression Therapy; Magnetic Resonance Imaging; Myeloablative Agonists; Osteosarcoma; Pleural Neoplasms; Radiography, Thoracic; Vidarabine | 2006 |